Skip to Main content Skip to Navigation

Brevetabilité des médicaments et innovation pharmaceutique en Tunisie : étude théorique et validation empirique

Abstract : The theoretical study of the impact of patentability on pharmaceutical innovation reveals ambivalent relationships. Thus, it is interesting to target the analysis on a particular country. The notable growth of the local pharmaceutical industry, the emphasis put by the State on the encouragement of pharmaceutical R&D and the absence of previous studies on this issue, are as many factors that make from the Tunisian pharmaceutical industry an interesting cas study of the impact of drugs patentability on pharmaceutical innovation. After having studied the endogenous and exogenous innovation potential in Tunisia, first throughout an analysis of the sectoral national innovation system (SNIS), then according to a survey led next to the pharmaceutical laboratories in Tunisia, we have constructed an index measuring their innovation potential and performances and determined the impact of patentability. The empirical results show that patentability is an incentive for innovation only if the firm (industry, economy) transforms from a "net imitator" into a "net innovator". The Tunisian pharmaceutical industry being at a stage of a net imitator, drugs patentability generates a negative effect on local innovation on the short run and seems a premature reform in Tunisia. However, in the long run, the impact depends on the efficiency of the SNIS in putting into effect alternative means to access new technologies by creating a dynamic of attraction towards pharmaceutical foreign investments "innovation seeking". The theoretical developments, the empirical results and the lessons taught from foreign experiences suggest that this is as much realizable as the Tunisian state adopts a technological policy more targeted and better thought in a sense of creating a genuine "market" for pharmaceutical innovation, throughout valorizing the human capital and boosting the interactions between the public and private actors of the SNIS.
Document type :
Complete list of metadatas

Cited literature [455 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Friday, July 12, 2019 - 3:52:32 PM
Last modification on : Monday, December 14, 2020 - 6:12:33 PM


Version validated by the jury (STAR)


  • HAL Id : tel-02182129, version 1



Nejla Yacoub. Brevetabilité des médicaments et innovation pharmaceutique en Tunisie : étude théorique et validation empirique. Economies et finances. Université du Littoral Côte d'Opale; Institut des Hautes Etudes Commerciales (Sousse, Tunisie), 2012. Français. ⟨NNT : 2012DUNK0451⟩. ⟨tel-02182129⟩



Record views


Files downloads